Children’ Hospital of Philadelphia
Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer
The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival
Pfizer announces phase 3 results for potential non-small cell lung cancer treatment
Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer
Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022
Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients
Over 800,000 people worldwide live with haemophilia
Pfizer’s PADCEV gets FDA approval for bladder cancer
Bladder cancer affects more than 614,000 people globally each year
Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk
The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer
Pfizer’s Lorviqua recommended by NICE for lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide
Pfizer agrees pricing and distribution deal with US government
The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs
Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer
Around 55,100 cases of prostate cancer are diagnosed in the UK every year
Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi
Around 20% and 3% of haemophilia A and B patients, respectively, develop inhibitors
Pfizer shares ‘unprecedented’ survival results for Braftovi in colorectal cancer
Around 154,270 people are expected to be diagnosed with cancer of the colon or rectum in the US this year